Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Im

Showing results (251-260 of 279) with videos related to

Pageof 28
Sort By:
Bone Marrow Transplantation|September 28, 2018
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndromePiyanuch Kongtim, Simrit Parmar, Denái R Milton, et al.
Bone Marrow Transplantation|May 17, 2023
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplantTaha Al-Juhaishi, Yingjun Wang, Denái R Milton, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2011
Structural reorganization of the antigen-binding groove of human CD1b for presentation of mycobacterial sulfoglycolipidsLuis F Garcia-Alles, Anthony Collmann, Cees Versluis, et al.
Immunity|June 23, 2009
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activationJin S Im, Pooja Arora, Gabriel Bricard, et al.
Journal of Neurology|August 12, 2025
Multi-modal proton and sodium MRI for outcome prediction in mild traumatic brain injuryAnna M Chen, Teresa Gerhalter, Zhongyang Ma, et al.
Frontiers in Immunology|June 26, 2026
Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease modelAbel Trujillo-Ocampo, Pamella Borges, Maison Grefe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalD J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2021
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]D J Slamon, P Neven, S Chia, et al.
American Journal of Hematology|February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trialIssa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous TransplantIssa F Khouri, Denái R Milton, Alison M Gulbis, et al.
Pageof 28

Showing results (251-260 of 279) with videos related to

Sort By:
Pageof 28
Bone Marrow Transplantation|September 28, 2018
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndromePiyanuch Kongtim, Simrit Parmar, Denái R Milton, et al.
Bone Marrow Transplantation|May 17, 2023
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplantTaha Al-Juhaishi, Yingjun Wang, Denái R Milton, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2011
Structural reorganization of the antigen-binding groove of human CD1b for presentation of mycobacterial sulfoglycolipidsLuis F Garcia-Alles, Anthony Collmann, Cees Versluis, et al.
Immunity|June 23, 2009
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activationJin S Im, Pooja Arora, Gabriel Bricard, et al.
Journal of Neurology|August 12, 2025
Multi-modal proton and sodium MRI for outcome prediction in mild traumatic brain injuryAnna M Chen, Teresa Gerhalter, Zhongyang Ma, et al.
Frontiers in Immunology|June 26, 2026
Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease modelAbel Trujillo-Ocampo, Pamella Borges, Maison Grefe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalD J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2021
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]D J Slamon, P Neven, S Chia, et al.
American Journal of Hematology|February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trialIssa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous TransplantIssa F Khouri, Denái R Milton, Alison M Gulbis, et al.
Pageof 28